+ Watch STML
on My Watchlist
No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more attractive for a narrowly focused biopharma headed into pivotal trials of a largely unproven therapy for a potentially lucrative indication. Lock-up expiration activity is likely resolved and hedge fund transactions have lately been favorable. If the momentum reverses once the pivotal trials kick off in early 2014, I might tag a small chunk of speculative capital onto Stemline for the ride.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions